Yale University · Biomedical EngineeringAcute Leukemia Therapeutics Lab
Ranjit Bindra · New Haven, Connecticut
Research Focus
Dr. Ranjit Bindra's lab at Yale University focuses on understanding and treating acute myeloid leukemia (AML), particularly in patients with mutations in genes called IDH1 and IDH2. These mutations disrupt important DNA repair processes, making cancer cells vulnerable to specific therapies. The lab is investigating new ways to combine existing drugs to enhance treatment effectiveness, especially for patients who have not responded well to current therapies.
acute myeloid leukemiaDNA damage responseIDH1IDH2PARP inhibitorscancer therapyclinical trialsepigeneticsoncometabolites
Research Aims
4AIM 01Investigate the DNA damage response defects caused by IDH1/2 mutations in AML.
AIM 02Evaluate the effectiveness of DDR inhibitors in combination with other treatments.
AIM 03Study the impact of additional mutations on treatment response.
AIM 04Translate our findings into clinical trials for better AML therapies.
Skills the Lab Values
cell cultureDNA sequencingin vivo studiesflow cytometryWestern blottingxenograft modelsgene editingCRISPRbioinformaticsdrug efficacy testing
Output against the department
Publications382top 23% of dept.139th of 595
this lab
most publishedleast published
Citations9.6ktop 36% of dept.213th of 595
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.